CA-SENTRY
30.11.2022 16:01:37 CET | Business Wire | Press release
Sentry, the leader in developer-first application monitoring, today announced it has acquired Codecov, the leading dedicated code coverage reporting solution, providing developers with actionable insights into their workflow. The acquisition expands Sentry’s product offering for development teams to improve code quality and velocity even earlier in the development life cycle, helping to accelerate remediation and enabling the delivery of better end-user experiences.
“Our mission has always been to empower developers to ship high quality code, faster than anyone else through context and insights, versus dashboards and tools that frankly weren’t built for resolution,” said Milin Desai, CEO of Sentry. “The Codecov team shares this singular focus – and enables us to offer developers even more comprehensive insight into their application’s code quality earlier in the development cycle.”
Codecov is the leading dedicated code coverage solution, which helps thousands of development teams at companies like Lyft, Slack, Washington Post, GoodRx, and Alteryx, confidently ship stable code. Similar to Sentry, Codecov works within developers’ existing workflows for software development, providing feedback, insight, and ownership over the quality of code regardless of platform, language, or CI/CD tooling. With the acquisition, Sentry customers will benefit from insights and protection over their code quality both pre- and post-deployment.
"At Lyft, we want to help our developers reliably ship code as fast as possible by providing an environment that allows them to feel confident to make and ship changes in code," said Jun Li, Staff Software Engineer at Lyft. "Codecov provides a source of truth for our teams. It reduces friction as it is flexible enough to fit into any language and CI/CD so engineers can see the impact and dig deeper into code changes, all in one place. The implementation of Codecov has improved the overall developer experience and we're seeing more and more adoption of it across our teams.”
“From day one, our primary focus has been on using tools like code coverage to help developers ship quickly and reliably,” said Jerrod Engelberg, CEO of Codecov. “There’s an obvious alignment between Sentry and Codecov in how we empower developers to feel confident in making and shipping changes. We are climbing the same summit of software reliability from opposite sides, and with this, our customers new and old will experience faster development cycles, quicker discovery and remediation of bugs, and an overall better developer experience. ”
Codecov providing intelligent code coverage furthers Sentry’s commitment to addressing the evolving needs of software developers who are using tooling that is not purpose-built for their workflows or their most pressing problems. The addition of Codecov, along with Sentry’s other recent investments will serve to evolve application monitoring for software developers everywhere.
Codecov’s talented and experienced team, including co-founders Jerrod Engelberg and Eli Hooten, will join the Sentry team.
Read the Sentry and Codecov blogs to learn more about how the companies will work together to bring a new level of actionable insight directly into the developer’s workflow.
About Sentry
For software teams, Sentry is essential for monitoring application code quality. From Error tracking to Performance monitoring, developers can see clearer, solve quicker, and learn continuously about their applications — from frontend to backend. Loved by more than 3.5 million developers and 85,000 organizations worldwide, Sentry provides code-level observability to many of the world’s best-known companies like Disney, Cloudflare, Eventbrite, Slack, Supercell, and Rockstar Games. Learn more at sentry.io or follow Sentry on GitHub, Twitter, Dribbble, or LinkedIn.
About Codecov
Codecov is the leading dedicated code coverage reporting solution focused on helping developers quickly ship reliable code while helping engineering teams save time and improve the overall developer experience. The company helps thousands of development teams at some of the world’s largest companies like Lyft, Slack, Washington Post, GoodRx, and Alteryx, confidently deliver stable and bug-free code with highly integrated tools to surface coverage insights where they are needed.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221129006193/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Interactive Brokers Integrates AI into Client Portfolios – Informed by Agentic Technology, Controlled by the Client1.6.2026 16:00:00 CEST | Press release
Clients Can Research Stocks, Analyze Performance, and Generate Trade Instructions in Claude. The Client Approves Every Trade. Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced agentic trading through direct integration with Claude, one of the world's leading AI platforms. Available through the AI platform’s certified connector marketplace, the integration lets clients manage their accounts and access more than 170 global markets. "Interactive Brokers has used technology for over four decades to help investors make more informed decisions and interact more efficiently with markets," said Milan Galik, Chief Executive Officer of Interactive Brokers. "Investors are increasingly using artificial intelligence to research markets, analyze information and generate ideas. We believe the next logical step is to allow clients to securely connect AI tools directly to their brokerage accounts — whether they want a simple conversational interface, deeper portfolio analy
AIM Expands Life Sciences Supply Chain Capabilities and Hires New Partner, Thomas Ebel1.6.2026 15:01:00 CEST | Press release
AIM today announced the appointment of veteran pharma supply chain expert Thomas Ebel as Partner, effective June 15. Mr. Ebel brings more than 25 years of supply chain consulting experience at leading firms including CAMELOT, McKinsey, and Accenture, and will anchor a broader initiative to expand AIM’s end-to-end supply chain capabilities. According to Richard de Bakker, Statutory Director and Founder at AIM, the firm is significantly expanding its capabilities around “end-to-end” supply chain needs. “AIM is well known as a leader in supply chain development for launch, as well as optimization of existing supply chains — supporting clients in getting their finished products to patients,” said Mr. de Bakker. “We are now adding new capabilities in supply chain diagnostics and strategy, end-to-end planning optimization, supply reliability, and working capital optimization, among others. Combined with AIM’s established supply chain expertise, this expanded offering gives clients true ‘end-
Seoul Semiconductor's World-First 'HV Opto-Semiconductor' Powers Up Global Top 4 Automakers1.6.2026 15:00:00 CEST | Press release
Seoul Semiconductor Co., Ltd. (KOSDAQ: 046890), a global opto-semiconductor technology company, announced that its world's first High Voltage (HV) opto-semiconductor technology has entered mass production with four of the world's top automotive brands across the Americas, Europe, and Asia, with plans to expand supply to 10 models by the end of the year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260601232986/en/ Comparison: Conventional 3V LED vs. Seoul Semiconductor 12V 'HV Opto-Semiconductor' (Figure: Seoul Semiconductor) The technology combines micro-scaled opto-semiconductor chips capable of 12V single-chip operation — as opposed to conventional 3V LEDs — with a high-voltage (HV) driver technology. This enables a reduction of more than 10% in the number of driver-related components used in hybrid and electric vehicles, while lowering power consumption by approximately 10%, contributing to cost reduction and simplific
Oscilloquartz delivers assured timing for mission-critical harsh environments with ruggedSync™ Series OSA 55101.6.2026 14:00:00 CEST | Press release
News summary: Defense operations require resilient timing architectures that maintain synchronization in contested and GNSS-denied environments ruggedSync™ Series OSA 5510 delivers assured timing and extended holdover in a MIL-qualified platform for tactical, deployable operations Zero-trust resiliency with diversified cPNT sources, including M-Code, PRS and STL, strengthens operational continuity for defense communications, navigation and mission-critical infrastructure Oscilloquartz today launched its ruggedSync™ Series OSA 5510, a ruggedized timing and synchronization platform engineered for defense and other harsh, mission-critical environments. Designed for deployment in tactical communications networks, mobile command centers (MCCs), aviation systems and other highly demanding operational environments, the OSA 5510 combines PTP grandmaster and NTP server functionality with synchronization assurance and resilient holdover in a compact MIL-qualified platform. Multi-band GNSS suppor
Vertex Announces US FDA Acceptance of Biologics License Application for Accelerated Approval of Povetacicept in IgA Nephropathy1.6.2026 14:00:00 CEST | Press release
- FDA assigns Prescription Drug User Fee Act (PDUFA) target action date of November 30, 2026 – Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) submission for povetacicept, an investigational engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in adults with immunoglobulin A nephropathy (IgAN). The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of November 30, 2026. If approved, povetacicept will become the first commercialized therapy in Vertex’s emerging nephrology franchise. “The Phase 3 RAINIER trial is the largest conducted in IgAN and achieved full enrollment faster than any contemporary IgAN trial, reflecting the significant unmet need in IgAN and our urgency to bring povetacicept to patients with this serious disease,” said Nia Tatsis, Ph.D., Executi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom